Skandinaviska Enskilda Banken Ab (Publ) Karuna Therapeutics, Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$161.01 - $317.85 $8.92 Million - $17.6 Million	55,374 Added 622.25%	64,273 $20.3 Million
Q3 2023 Nov 09, 2023	BUY	$164.66 - $218.08 $394,854 - $522,955	2,398 Added 36.89%	8,899 $1.51 Million
Q2 2023 Aug 07, 2023	BUY	$176.32 - $240.22 $590,143 - $804,016	3,347 Added 106.12%	6,501 $1.41 Million
Q1 2023 May 11, 2023	BUY	$161.33 - $204.36 $508,834 - $644,551	3,154 New	3,154 $573,000
Q3 2020 Nov 12, 2020	SELL	$71.31 - $109.74 $28,524 - $43,896	-400 Closed	0 $0

Q2 2020 Aug 13, 2020	BUY	$62.14 - $117.21 $24,856 - $46,884	400 New	400 $45,000

333K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.